Compare Neurocrine Biosciences Inc (NBIX) vs Veritone Inc (VERI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs Veritone Inc — how do they compare? Neurocrine Biosciences Inc trades at $143.25 (market cap $14.36B), while Veritone Inc trades at $0.58 (market cap $59.46M). The key difference: Neurocrine Biosciences Inc is far larger — about 241.5× Veritone Inc's market cap, and Neurocrine Biosciences Inc is trading nearer its 52-week high, Veritone Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Neurocrine Biosciences Inc for 23 Days and Veritone Inc for 12 Days on average.
| NBIX | VERI | |
|---|---|---|
Market Cap | $14.36B | $59.46M |
Volume | 1,237,180 | 15,523,164 |
Sector | Health | Technology |
52-Week High | $185.50 | $8.39 |
52-Week Low | $123.10 | $0.59 |
Typical Hold Time | 23 Days | 12 Days |
Enterprise Value | $14.37B | $94.86M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $141.69, down 1.24% on the day, with a bearish technical signal from moving averages. Fundamentally, the company shows strong profitability with a 20.91% net income margin and consistent earnings beats, including a significant Q2 2026 beat. Recent news highlights pipeline advancements and executive appointments, while analyst sentiment remains overwhelmingly positive.
The outlook for NBIX is supported by robust fundamentals and strong analyst buy ratings, but near-term price action is challenged by technical bearishness. Key opportunities include product diversification and pipeline growth, while risks involve execution of expansion plans and potential pricing pressures on key products like INGREZZA.
Veritone (VERI) trades at $0.61, down 11.76% in the last 24 hours, reflecting bearish technical signals. The company reported a net loss of $111.73 million in 2025, with negative profit margins and cash flow challenges, though revenue remains near $92 million. Recent news includes a $15 million equity offering and partnerships, but legal investigations and persistent losses weigh on sentiment.
The outlook is highly speculative, with a consensus price target of $3.75 suggesting significant upside if the company achieves profitability. However, high execution risk, cash burn, and legal overhangs present substantial downside, making the stock suitable only for risk-tolerant investors betting on a turnaround.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About Veritone Inc
Veritone is a leading provider of enterprise AI software and solutions, centered on its proprietary AI operating system, aiWARE™. The platform orchestrates a vast ecosystem of machine learning models to transform unstructured data—such as audio, video, and text—into actionable intelligence. Serving the media, entertainment, and public sectors, Veritone is a critical infrastructure partner for organizations looking to monetize data archives and operationalize AI at scale.
Read more on VERI →
